




ENVISION

GROWTH

with
the Côte d'Azur

OPHTHALMOLOGY
CLUSTER

 Invest in Côte d'Azur,
the Blue Chip Coast




CÔTE D'AZUR: BE PART OF CLUSTER UNRIVALLED

THE CLUSTER ENCOMPASSES EVERY
STAGE OF OPHTHALMIC DRUG
DEVELOPMENT AND EVERY SECTOR
OF ACTIVITY IN THE FIELD.



THEY HAVE ALREADY CHOSEN
CÔTE D'AZUR AND MONACO
FOR THEIR BUSINESS DEVELOPMENT:

ALLERGAN
AMO (ABBOTT)
COOPERVISION
EUROPHTA (THEA)
HORUS PHARMA
IMMUNOSEARCH
IRIS PHARMA
LABORATOIRES GENEVRIER
NICOX
OCTALIA
OPHTALMIS (THEA)
QUANTIFICARE
SYNOPTIC (MXM)
VIRBAC





AN INDUSTRIAL KNOWLEDGE IN EUROPE

Testimonial

▶ CooperVision

*World's second largest contact lens manufacturer -
Number one maker of toric contact lenses for
the correction of astigmatism.*

"CooperVision France has chosen to set up its headquarters in Sophia Antipolis, 90 minutes far from Paris by plane. Since its creation in 1968, Sophia Antipolis science and technology park has always been the leading place in Europe for innovative companies. In this studios, innovative and nature-orientated environment, CooperVision feels perfectly at ease to carry on developing its activities."

*Vincent Brenckmann,
General manager CooperVision France*

Testimonial

▶ Europhta (Laboratoires THEA)

*A specialist laboratory for ocular single-dose products –
part of Laboratoires THEA, number 8 in the world and
number 1 independent family owned company in Europe
in ophthalmology sector.*

"Europhta has found here all the ingredients for a company to attract talented people and grow successfully: an international and multicultural metropolis, an easy access worldwide for business collaborators via Nice international airport, a place combining scientific excellence and dynamic business environment and of course a matchless quality of life."

*Isabelle Duménil,
Head Pharmacist - Pharmaceutical Director Europhta*

Beyond private companies and public research institutes, the strength of the cluster also comes from a strong local network of ophthalmologists in private practices as well as in hospitals, superior to national average.

OPHTA BIOTECH – RIVIERA

A UNIQUE COLLABORATIVE AT ANSWERING PATIENTS'

- ▶ MISSION: TO PROMOTE THE EMERGENCE OF NEW PROJECTS AND TOOLS TO COMBAT THE ENTIRE RANGE OF PATHOLOGIES AFFECTING VISUALLY IMPAIRED PATIENTS.

“Ophta Biotech is a unique platform in Europe involving 40 members from Côte d'Azur, Monaco and Corsica, and covering the whole ophthalmology industry, from fundamental research to therapy.”

Pierre Paul Elena, Iris Pharma, Founding Member of Ophta Biotech

In order to get a global approach of all ocular pathologies, the founding members of the association (2 companies - Iris Pharma and Horus Pharma -, the head of ophthalmology department of Nice Hospital and an ophthalmologist) have decided to gather complementary competences:

- Patients' associations
- Hospitals
- Researchers from public and private bodies
- Health professionals (ophthalmologists and orthoptists)
- Pharmaceutical, biotech and medical equipment companies
- Service providers




- ▶ TARGET: THE EFFECTIVE IMPROVEMENT OF DAILY LIFE OF PATIENTS AFFECTED BY EYE PATHOLOGIES.

- Analysis, labeling and support of innovative research projects improving patients' life
- Innovative technologies at the disposal of patients
- Reinforced collaboration between public research institutes and private companies to strengthen the expertise of the cluster
- Promotion of the potential of Ophta Biotech members worldwide and networking with the whole ophthalmology community

“Ophta Biotech is able to address the increased demand for ophthalmology care and treatment by covering all the ocular pathologies : Age-related macular degeneration (AMD), Diabetic retinopathy, Glaucoma, Ocular inflammation, Ocular infection, Ocular allergy, Dry eye syndrome, Visual defects, Orphan diseases...”

Claude Claret, Horus Pharma, Founding Member of Ophta Biotech



LOW VISION CENTER:
a project already under way.

This usage lab will showcase pilot technologies developed to improve daily life of visually impaired patients

OPHTHA VALLEY

PLATFORM AIMING NEEDS


▶ A LOCAL BASE, AN INTERNATIONAL INFLUENCE:

Ophta Biotech, being an international collaborative platform, is a natural partner of all the ophthalmology national actors. Its partnership with the "Institut de la Vision" in Paris will ensure a direct access to a worldwide research network.



CYCLOTRON:


An example of the long-established pool of excellence in therapy in publicly-funded research.



The nuclear medicine and radiotherapy center is a leading local center of excellence in basic and clinical research. Since 1991, the Cyclotron has been used to treat 3,500 European patients suffering from choroidal melanomas, making this the world's third largest treatment cohort.

Apart from this referral center for ocular oncology, the Nice hospital is also home to a referral center for vitreoretinal surgery.

CÔTE D'AZUR: R&D INCENTIVES FOR INNOVATIVE COMPANIES



▶ REGIONAL DEVELOPMENT GRANT SCHEME FOR RESEARCH, DEVELOPMENT AND INNOVATION (PAT RDI)

The PAT RDI is a state-financed investment subsidy to promote R&D activities. The purpose is to finance a R&D project that will result in a standard, design, methodology, or economic notion that can be viably industrialized or exported.

Subsidized programs must either lead to the creation of at least 20 permanent jobs or involve a minimum of € 7,5 millions in eligible investments.

The grant represents a subsidy of up to € 15,000 per job created for the R&D program for which the subsidy is requested.

▶ BEST RESEARCH TAX CREDIT IN EUROPE


The research tax credit (CIR) is a public grant aimed at increasing companies' competitiveness by backing their R&D efforts (fundamental, applied or experimental research). The CIR consists of a tax reduction that can be granted to any company subject to corporate income tax in France.

The tax credit represents 30% of the annual R&D expenditure (upt to 100 million € expenditure), and for companies benefiting for the first time of the CIR, the rate reaches 50% the first year and 40% the second year.

▶ YOUNG INNOVATIVE COMPANIES STATUS (JEI)

This status is given to SMEs having less than 8 years of existence, being independent and with research and development costs representing at least 15% of their expenses.

The advantages consist of tax relief and partial exemption of employer's social contributions.



France: the most favourable R&D tax incentive in OECD countries

CÔTE D'AZUR: THE CHOICE OF A VIBRANT ENVIRONMENT FOR SCIENCE AND INDUSTRY

- A leading destination in France for foreign R&D investments
- Sophia Antipolis: the leading European science and technology park hosting more than 1,400 companies
- A diversified industrial fabric made of large groups backed by a thriving community of smaller innovative companies
- An international metropolis : 160 nationalities
- Public research: a strong innovative impulse with 130 public research labs employing 2,000 researchers
- A reservoir of know-how with 36,000 skilled and multicultural students from the University, management and engineering Schools
- A magnet to young though skilled and mobile talents
- An international fame and attractiveness that makes it a well attended rendez-vous in Europe for business visitors
- Real Estate : a “global place” at “village” price



*Springboard your company worldwide via
Nice International Airport!*

Nice airport : 2nd airport in France

10 Million
passengers

100 destinations
to **30** countries

**New York Direct
Flight** | daily

**Business low cost
leader** in France

52% of
international
passengers

Less
than **2 hours**
away from Major
European Capitals

25 connections
are serviced by
same day return flights

**Frequent flyers
fast track**
to boarding zone program

Europe

Paris: 34 daily (easyJet, Air France)
London: 20 daily (AirFrance, easyJet, BA)
Munich: 4 daily (Air Berlin, Lufthansa)
Frankfurt: 4 daily (Lufthansa)
Barcelona: 4 daily (Iberia)
Milan: 3 daily (Alitalia)



 Invest in Côte d'Azur,
the Blue Chip Coast



TEAM CÔTE D'AZUR: YOUR PARTNER FOR SETTING UP YOUR COMPANY ON CÔTE D'AZUR

*We hope to
welcome you soon
in Côte d'Azur!*



**T E A M
C Ô T E
D ' A Z U R**

CREATIVITY FOR BUSINESS

THE CÔTE D'AZUR ECONOMIC DEVELOPMENT AGENCY

CONTACT: Céline Jacquet
cjacquet@teamcotedazur.fr

400, Promenade des Anglais - BP 3185
06204 NICE CEDEX 3 - FRANCE
Tel: 33 (0)4 92 17 51 51
info@investincotedazur.com

www.investincotedazur.com



CONTACT : Katia Barcaroli
contact@ophtabiotech.asso.fr

Cap Var, Bâtiment D2
148, avenue Georges Guynemer
06700 SAINT-LAURENT-DU-VAR – FRANCE